176 related articles for article (PubMed ID: 27914970)
1. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?
Buske C
Lancet Haematol; 2017 Jan; 4(1):e4-e5. PubMed ID: 27914970
[No Abstract] [Full Text] [Related]
2. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies for Waldenström Macroglobulinemia.
Dominguez A; Kastritis E; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):841-852. PubMed ID: 30190022
[TBL] [Abstract][Full Text] [Related]
4. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia.
Weide R; Heymanns J; Köppler H
Leuk Lymphoma; 1999 Dec; 36(1-2):203-6. PubMed ID: 10613467
[TBL] [Abstract][Full Text] [Related]
5. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
7. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis.
Khaled Y; Hanbali A
Am J Hematol; 2007 Jul; 82(7):688. PubMed ID: 17366549
[No Abstract] [Full Text] [Related]
9. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.
Weide R; Heymanns J; Köppler H
Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038
[TBL] [Abstract][Full Text] [Related]
10. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
[No Abstract] [Full Text] [Related]
11. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
12. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
13. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
15. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia].
Holmström MO
Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
18. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis.
Genzen JR; Kawaguchi KR; Furman RR
Br J Haematol; 2011 Oct; 155(1):123-5. PubMed ID: 21521182
[No Abstract] [Full Text] [Related]
19. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age.
Babwah A; Gustine J; Meid K; Dubeau T; Xu L; Yang G; Hunter ZR; Treon SP; Castillo JJ
Br J Haematol; 2019 May; 185(4):799-802. PubMed ID: 30407630
[No Abstract] [Full Text] [Related]
20. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
